Literature DB >> 33077894

JARID2 haploinsufficiency is associated with a clinically distinct neurodevelopmental syndrome.

Eline A Verberne1, Shuxiang Goh2, Jade England3, Mieke M van Haelst4, Philippe M Campeau5, Manon van Ginkel1,6, Louise Rafael-Croes6, Saskia Maas1, Abeltje Polstra1, Yuri A Zarate7, Katherine A Bosanko7, Kieran B Pechter8, Emma Bedoukian9, Kosuke Izumi9, Ayeshah Chaudhry10,11, Nathaniel H Robin12, Megan Boothe12, Natalie C Lippa13, Vimla Aggarwal13, Darryl C De Vivo14, Anna Lehman15, Causes Study15, Sylvia Stockler16, Ange-Line Bruel17, Bertrand Isidor18, Jennifer Lemons19, David F Rodriguez-Buritica19, Christopher M Richmond20,21, Zornitza Stark20,22, Pankaj B Agrawal23, R Frank Kooy24, Marije E C Meuwissen24,25, David A Koolen26, Rolf Pfundt26, Agne Lieden27,28, Britt-Marie Anderlid27,28, Dagmar Glatz29, Marcel M A M Mannens1, Madhura Bakshi2, Frédérick A Mallette29.   

Abstract

PURPOSE: JARID2, located on chromosome 6p22.3, is a regulator of histone methyltransferase complexes that is expressed in human neurons. So far, 13 individuals sharing clinical features including intellectual disability (ID) were reported with de novo heterozygous deletions in 6p22-p24 encompassing the full length JARID2 gene (OMIM 601594). However, all published individuals to date have a deletion of at least one other adjoining gene, making it difficult to determine if JARID2 is the critical gene responsible for the shared features. We aim to confirm JARID2 as a human disease gene and further elucidate the associated clinical phenotype.
METHODS: Chromosome microarray analysis, exome sequencing, and an online matching platform (GeneMatcher) were used to identify individuals with single-nucleotide variants or deletions involving JARID2.
RESULTS: We report 16 individuals in 15 families with a deletion or single-nucleotide variant in JARID2. Several of these variants are likely to result in haploinsufficiency due to nonsense-mediated messenger RNA (mRNA) decay. All individuals have developmental delay and/or ID and share some overlapping clinical characteristics such as facial features with those who have larger deletions involving JARID2.
CONCLUSION: We report that JARID2 haploinsufficiency leads to a clinically distinct neurodevelopmental syndrome, thus establishing gene-disease validity for the purpose of diagnostic reporting.

Entities:  

Keywords:  JARID2; developmental delay; intellectual disability; neurodevelopment

Mesh:

Substances:

Year:  2020        PMID: 33077894     DOI: 10.1038/s41436-020-00992-z

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  40 in total

1.  JARID2 regulates binding of the Polycomb repressive complex 2 to target genes in ES cells.

Authors:  Diego Pasini; Paul A C Cloos; Julian Walfridsson; Linda Olsson; John-Paul Bukowski; Jens V Johansen; Mads Bak; Niels Tommerup; Juri Rappsilber; Kristian Helin
Journal:  Nature       Date:  2010-03-11       Impact factor: 49.962

2.  Jarid2 and PRC2, partners in regulating gene expression.

Authors:  Gang Li; Raphael Margueron; Manching Ku; Pierre Chambon; Bradley E Bernstein; Danny Reinberg
Journal:  Genes Dev       Date:  2010-02-01       Impact factor: 11.361

3.  Characterization of the human jumonji gene.

Authors:  J L Bergé-Lefranc; P Jay; A Massacrier; P Cau; M G Mattei; S Bauer; C Marsollier; P Berta; M Fontes
Journal:  Hum Mol Genet       Date:  1996-10       Impact factor: 6.150

4.  Jarid2 (Jumonji, AT rich interactive domain 2) regulates NOTCH1 expression via histone modification in the developing heart.

Authors:  Matthew R Mysliwiec; Clayton D Carlson; Josh Tietjen; Holly Hung; Aseem Z Ansari; Youngsook Lee
Journal:  J Biol Chem       Date:  2011-11-21       Impact factor: 5.157

Review 5.  Roles of JUMONJI in mouse embryonic development.

Authors:  Jooyoung Jung; Matthew R Mysliwiec; Youngsook Lee
Journal:  Dev Dyn       Date:  2005-01       Impact factor: 3.780

Review 6.  Notch signaling in the mammalian central nervous system: insights from mouse mutants.

Authors:  Keejung Yoon; Nicholas Gaiano
Journal:  Nat Neurosci       Date:  2005-06       Impact factor: 24.884

7.  Jarid2/Jumonji coordinates control of PRC2 enzymatic activity and target gene occupancy in pluripotent cells.

Authors:  Jamy C Peng; Anton Valouev; Tomek Swigut; Junmei Zhang; Yingming Zhao; Arend Sidow; Joanna Wysocka
Journal:  Cell       Date:  2009-12-24       Impact factor: 41.582

8.  A jumonji (Jarid2) protein complex represses cyclin D1 expression by methylation of histone H3-K9.

Authors:  Haruki Shirato; Satoko Ogawa; Kuniko Nakajima; Masayo Inagawa; Mizuyo Kojima; Makoto Tachibana; Yoichi Shinkai; Takashi Takeuchi
Journal:  J Biol Chem       Date:  2008-11-14       Impact factor: 5.157

9.  Jarid2 Coordinates Nanog Expression and PCP/Wnt Signaling Required for Efficient ESC Differentiation and Early Embryo Development.

Authors:  David Landeira; Hakan Bagci; Andrzej R Malinowski; Karen E Brown; Jorge Soza-Ried; Amelie Feytout; Zoe Webster; Elodie Ndjetehe; Irene Cantone; Helena G Asenjo; Neil Brockdorff; Thomas Carroll; Matthias Merkenschlager; Amanda G Fisher
Journal:  Cell Rep       Date:  2015-07-16       Impact factor: 9.423

10.  Jumonji modulates polycomb activity and self-renewal versus differentiation of stem cells.

Authors:  Xiaohua Shen; Woojin Kim; Yuko Fujiwara; Matthew D Simon; Yingchun Liu; Matthew R Mysliwiec; Guo-Cheng Yuan; Youngsook Lee; Stuart H Orkin
Journal:  Cell       Date:  2009-12-24       Impact factor: 41.582

View more
  2 in total

1.  DNA Methylation Signature for JARID2-Neurodevelopmental Syndrome.

Authors:  Eline A Verberne; Liselot van der Laan; Sadegheh Haghshenas; Kathleen Rooney; Michael A Levy; Mariëlle Alders; Saskia M Maas; Sandra Jansen; Agne Lieden; Britt-Marie Anderlid; Louise Rafael-Croes; Philippe M Campeau; Ayeshah Chaudhry; David A Koolen; Rolph Pfundt; Anna C E Hurst; Frederic Tran-Mau-Them; Ange-Line Bruel; Laetitia Lambert; Bertrand Isidor; Marcel M A M Mannens; Bekim Sadikovic; Peter Henneman; Mieke M van Haelst
Journal:  Int J Mol Sci       Date:  2022-07-20       Impact factor: 6.208

2.  Genetic care in geographically isolated small island communities: 8 years of experience in the Dutch Caribbean.

Authors:  Eline A Verberne; Jonne M Westermann; Tamar I de Vries; Ginette M Ecury-Goossen; Shirley M Lo-A-Njoe; Meindert E Manshande; Sonja Faries; Hans D Veenhuis; Patricia Philippi; Farah A Falix; Irsa Rosina-Angelista; Maria Ponson-Wever; Louise Rafael-Croes; Patricia Thorsen; Eric Arends; Maartje de Vroomen; Sietse Q Nagelkerke; Martijn Tilanus; Lars T van der Veken; Karin Huijsdens-van Amsterdam; Anne-Marie van der Kevie-Kersemaekers; Mariëlle Alders; Marcel M A M Mannens; Mieke M van Haelst
Journal:  Am J Med Genet A       Date:  2022-03-07       Impact factor: 2.578

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.